In the past decade, several novel biomarkers have been used to assess myocardial injury, for example, copeptin2, pentraxin-33, heart type-fatty acid binding protein (H-FABP)4, procalcitonin5, vaspin6, myeloperoxidase7, and interleukin-68, and the diagnostic and prognostic capabilities of these myocardial stretch, inflammatory and oxidative stress biomarkers in patient with stable coronary heart disease (SCHD) have been established. The gene discussed is FABP3; the disease is coronary artery disorder.